Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg·day-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking.
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) / Francesco, S., Paola, C., Stefano, C., Michele, M., Nicola, P., Paolo, B., Giuseppe, L., Donato, L., Antonio, V., Nicoletta, C., Marcella, M., Nicolò, R., Gianfranco Umberto, M., Barbara, R., Collaborative Group, M., Confalonieri, M., Collaborative Group, M., Maria Citton, G., Lapadula, G., Bozzi, C., et al.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 61:4(2023), pp. 1-10. [10.1183/13993003.01514-2022]
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)
Micaela Romagnoli;Antonello Pietrangelo;Elena Corradini;Davide Bocchi;Chiara Boarini;
2023
Abstract
Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg·day-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2201514.full.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
937.91 kB
Formato
Adobe PDF
|
937.91 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
